Credit Suisse Has Just Reaffirmed $128.0 Target Price Per Share on Celgene (NASDAQ:CELG) stock, While They’ve Also Reiterated Their “Buy” Rating

January 21, 2018 - By Adrian Mccoy

 Credit Suisse Has Just Reaffirmed $128.0 Target Price Per Share on Celgene (NASDAQ:CELG) stock, While They’ve Also Reiterated Their

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.17, from 1.34 in 2017Q2. It turned negative, as 44 investors sold Celgene Corporation shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported.

Eagle Ridge Inv Management holds 0.37% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 15,259 shares. Wealthfront invested 0.07% in Celgene Corporation (NASDAQ:CELG). Pinebridge Invs Limited Partnership owns 0.12% invested in Celgene Corporation (NASDAQ:CELG) for 35,360 shares. M Holding Secs invested in 1,430 shares or 0.07% of the stock. First Citizens Bank & Trust And Communications invested in 0.18% or 9,268 shares. Us Bank De owns 797,087 shares. Retail Bank Of Hawaii reported 19,330 shares. North Star Inv Mgmt Corp reported 27,260 shares. Churchill Mngmt Corp invested 0.17% in Celgene Corporation (NASDAQ:CELG). Atalanta Sosnoff Cap Ltd Liability Corp stated it has 277,980 shares. Wilbanks Smith & Thomas Asset Mngmt Limited Liability Company reported 3,689 shares. Beech Hill Advsrs has invested 0.26% in Celgene Corporation (NASDAQ:CELG). Moors And Cabot Incorporated invested in 0.09% or 4,193 shares. Teachers Retirement Of The State Of Kentucky has invested 0.6% in Celgene Corporation (NASDAQ:CELG). Wetherby Asset Management accumulated 14,801 shares.

Since August 2, 2017, it had 0 insider buys, and 5 selling transactions for $6.27 million activity. The insider Curran Terrie sold 1,727 shares worth $248,498. $1.29 million worth of Celgene Corporation (NASDAQ:CELG) was sold by CASEY MICHAEL D. KAPLAN GILLA had sold 9,250 shares worth $1.31 million on Tuesday, September 12.

Celgene (NASDAQ:CELG) Rating Reaffirmed

Stock research analysts at Credit Suisse now has a $128.0 PT on Celgene (NASDAQ:CELG). Credit Suisse and their recent PT would indicate a potential upside of 24.70 % from the company’s previous stock close. The rating has been disclosed in analysts note on Monday morning.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.17, from 1.34 in 2017Q2. It turned negative, as 44 investors sold Celgene Corporation shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported.

Eagle Ridge Inv Management holds 0.37% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 15,259 shares. Wealthfront invested 0.07% in Celgene Corporation (NASDAQ:CELG). Pinebridge Invs Limited Partnership owns 0.12% invested in Celgene Corporation (NASDAQ:CELG) for 35,360 shares. M Holding Secs invested in 1,430 shares or 0.07% of the stock. First Citizens Bank & Trust And Communications invested in 0.18% or 9,268 shares. Us Bank De owns 797,087 shares. Retail Bank Of Hawaii reported 19,330 shares. North Star Inv Mgmt Corp reported 27,260 shares. Churchill Mngmt Corp invested 0.17% in Celgene Corporation (NASDAQ:CELG). Atalanta Sosnoff Cap Ltd Liability Corp stated it has 277,980 shares. Wilbanks Smith & Thomas Asset Mngmt Limited Liability Company reported 3,689 shares. Beech Hill Advsrs has invested 0.26% in Celgene Corporation (NASDAQ:CELG). Moors And Cabot Incorporated invested in 0.09% or 4,193 shares. Teachers Retirement Of The State Of Kentucky has invested 0.6% in Celgene Corporation (NASDAQ:CELG). Wetherby Asset Management accumulated 14,801 shares.

Since August 2, 2017, it had 0 insider buys, and 5 selling transactions for $6.27 million activity. The insider Curran Terrie sold 1,727 shares worth $248,498. $1.29 million worth of Celgene Corporation (NASDAQ:CELG) was sold by CASEY MICHAEL D. KAPLAN GILLA had sold 9,250 shares worth $1.31 million on Tuesday, September 12.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 18 have Buy rating, 2 Sell and 13 Hold. Therefore 55% are positive. Celgene Corporation has $190 highest and $83 lowest target. $134.07’s average target is 30.61% above currents $102.65 stock price. Celgene Corporation had 125 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Friday, December 22 by SunTrust. Leerink Swann maintained Celgene Corporation (NASDAQ:CELG) rating on Friday, October 20. Leerink Swann has “Buy” rating and $156.0 target. The stock of Celgene Corporation (NASDAQ:CELG) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The stock has “Buy” rating by Cowen & Co on Thursday, July 27. The rating was upgraded by Leerink Swann to “Outperform” on Friday, June 16. Piper Jaffray maintained the shares of CELG in report on Thursday, December 21 with “Hold” rating. The company was maintained on Monday, January 8 by Credit Suisse. The stock has “Buy” rating by Stifel Nicolaus on Monday, January 8. The firm earned “Outperform” rating on Wednesday, January 20 by Credit Suisse. The firm has “Buy” rating given on Thursday, October 26 by Cowen & Co.

The stock increased 0.91% or $0.93 during the last trading session, reaching $102.65. About 8.11 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since January 21, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 25. They expect $1.75 EPS, up 24.11 % or $0.34 from last year’s $1.41 per share. CELG’s profit will be $1.38B for 14.66 P/E if the $1.75 EPS becomes a reality. After $1.78 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -1.69 % negative EPS growth.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $80.82 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 24.06 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “Why The Juno Acquisition Talks Leaked” on January 18, 2018, also Investorplace.com with their article: “Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive” published on January 19, 2018, Seekingalpha.com published: “Celgene – Strong Portfolio Should Support Growing Earnings” on January 09, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Businesswire.com and their article: “Celgene Corporation Announces Preliminary 2017 Unaudited Results and 2018 …” published on January 08, 2018 as well as Seekingalpha.com‘s news article titled: “Celgene: Impact Biomedicines To Broaden The Pipeline” with publication date: January 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.